# Wegovy maker Novo Nordisk said surging demand for its first weight loss pill has put it on track to beat trading forecasts.

*biotech · news · 2026-05-06 · LBC*

## Key points

- Novo Nordisk's Wegovy pill launch is the strongest of any US obesity drug to date.
- The company has reported over two million Wegovy pill prescriptions since its January launch.
- Quarterly Wegovy pill sales were 2.26 billion Danish krone, surpassing analyst expectations.
- Novo Nordisk raised 2026 guidance for adjusted sales and operating profit due to Wegovy's success.
- Wegovy is currently the only oral peptide therapy for obesity on the market.

**Companies:** Novo Nordisk, Eli Lilly
**Countries:** Denmark, United States

[Read the full story on LBC](https://www.lbc.co.uk/article/8773737af8e141e180f5dfb365eccdca-5HjdYmC_2/)

---

Canonical: https://newsio.io/n/2ac55e19-c46f-40be-aaff-dab1c3ad5085/wegovy-maker-novo-nordisk-said-surging-demand-for-its-first-weight-loss-pill-has
Summarized by Newsio from LBC. https://newsio.io/how-it-works